NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 4 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Modi Naturals Subsidiary Bags ₹495 Cr Ethanol Supply Order from OMCs
Modi Naturals Limited's wholly owned subsidiary, Modi Biotech Private Limited, has secured orders from various Oil Marketing Companies (OMCs) to supply approximately 7.82 crore litres of ethanol. The orders carry an estimated value of approximately ₹495 crore, representing about 68.8% of the company's TTM revenue of ₹720 crore. Execution is scheduled across the Ethanol Supply Year (ESY) 2026-27, spanning November 2026 to October 2027. Additionally, the manufacturing process will produce by-products to be sold separately for incremental revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுModi Naturals' subsidiary has been formally awarded 7.82 crore litres in OMC ethanol allocation valued at ~₹495 crore for ESY 2026-27.
ஏன் இது முக்கியம்The ₹495 crore order secures significant revenue visibility for the next 12 months, equaling roughly 69% of Modi Naturals' total TTM turnover.
Order Value: ₹495 கோடிSupply Volume: 7.82 crore LitresExecution Period: நவம்பர் 2026 to அக்டோபர் 2027Order vs TTM Revenue: ~68.8%
📅 குறுகிய காலம்Positive sentiment driver given the substantial order size relative to the company's ₹437 crore market cap and baseline revenue.
📈 நீண்ட காலம்Validates the company's ethanol capacity expansion strategy, strengthening its position as a dedicated supplier to national OMCs.
⚠ அபாய எச்சரிக்கைகள்
Heavy client concentration in government OMC tenders
Raw material availability and grain feedstock price volatility impacting gross margins
👀 கவனிக்க வேண்டியவை
Track quarterly revenue and margin realization in the ethanol segment starting Q3 FY27 as ESY 2026-27 execution begins, alongside raw material feedstock pricing trends.
Modi Naturals Doubles Ethanol Plant Capacity to 600 KLPD at Subsidiary
Modi Naturals' wholly owned subsidiary, Modi Biotech Private Limited, has commenced commercial operations at its expanded grain-based ethanol facility in Chhattisgarh. The plant's total installed capacity increased from 282 KLPD to 600 KLPD, representing an addition of 318 KLPD of Ethanol/Rectified Spirit. The expanded production will cater to the government's Ethanol Blended Petrol (EBP) programme and should significantly drive volume growth over the company's TTM revenue base of ₹720 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுModi Biotech commenced commercial operations of its expanded ethanol plant, effectively more than doubling capacity from 282 KLPD to 600 KLPD.
ஏன் இது முக்கியம்A >110% increase in distillery capacity significantly scales production capacity, boosting Modi Naturals' primary revenue growth driver.
Original Capacity: 282 KLPDNew Total Capacity: 600 KLPDIncremental Capacity Added: 318 KLPDCapacity Increase: 112.8%
📅 குறுகிய காலம்Positive sentiment driver as the expanded facility begins commercial dispatches, with initial operational ramp-up visible in the next two quarters.
📈 நீண்ட காலம்Transforms Modi Naturals' scale in the grain-based ethanol segment, supporting structural revenue and EBITDA growth under the EBP framework.
⚠ அபாய எச்சரிக்கைகள்
Government policy risks regarding ethanol pricing and OMC offtake agreements
Grain feedstock availability and raw material price volatility
Modi Naturals Q2 FY27 Consolidated Revenue Up 38.9% YoY to ₹204.9 Cr, PAT Rises 9.4% to ₹11.0 Cr
Modi Naturals reported consolidated revenue from operations of ₹204.90 Cr for Q2 FY27, marking a 38.9% YoY growth compared to ₹147.47 Cr in Q2 FY26. Consolidated profit after tax (PAT) grew 9.4% YoY to ₹11.02 Cr, up from ₹10.07 Cr in the prior-year period, though it contracted sequentially from ₹12.50 Cr in Q1 FY27. For H1 FY27, consolidated revenue stood at ₹361.95 Cr with a net profit of ₹23.53 Cr. Basic EPS for the quarter was ₹8.33, compared to ₹7.58 in Q2 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates robust top-line growth driven by the expansion in bulk and subsidiary operations (ethanol), though margin compression led to slower PAT growth relative to revenue.
Consolidated Revenue (Q2 FY27): ₹204.90 கோடிConsolidated PAT (Q2 FY27): ₹11.02 கோடிConsolidated Revenue (H1 FY27): ₹361.95 கோடிConsolidated PAT (H1 FY27): ₹23.53 கோடிDiluted EPS (Q2 FY27): ₹8.33Revenue vs TTM Revenue: ~28.5%
📅 குறுகிய காலம்Market may view strong top-line momentum positively, though sequential contraction in net profit (from ₹12.50 Cr to ₹11.02 Cr) could keep sentiment measured.
📈 நீண்ட காலம்Growth remains anchored in scaling the ethanol division via Modi Biotech Private Limited alongside branded consumer product penetration.
⚠ அபாய எச்சரிக்கைகள்
Raw material costs surged to ₹157.68 Cr in Q2 FY27 from ₹100.02 Cr in Q2 FY26, squeezing operating margins
Standalone bulk segment posted an EBIT loss of ₹75.93 Lakhs in Q2 FY27
👀 கவனிக்க வேண்டியவை
Track operating margin stability against rising raw material costs and monitor progress on the ethanol capacity expansion to 310 KLPD targeted for late 2025/2026.
Modi Naturals' wholly owned subsidiary, Modi Biotech Private Limited (MBPL), has secured an additional allocation of 1.98 crore litres of ethanol with an estimated value of ₹140 crore for ESY 2025-26 from Oil Marketing Companies (OMCs). Supplies under this allocation are scheduled to run until October 2026. This award is incremental to the existing order of approximately ₹400 crore (~47.9k KL), taking the cumulative ESY 2025-26 order book to ~₹540 crore. The ₹140 crore incremental win constitutes ~42.4% of the company's TTM revenue of ₹330 crore, offering strong top-line visibility.
உச்சம் நம்பிக்கை
என்ன மாறியதுWholly owned subsidiary Modi Biotech secured an additional 1.98 crore litres (₹140 crore) ethanol supply allocation from OMCs for ESY 2025-26.
ஏன் இது முக்கியம்The win expands the ESY 2025-26 order book to ~₹540 crore, substantially exceeding the company's TTM revenue of ₹330 crore and bolstering distillery segment revenue visibility.
Additional order value: ₹ 140 croresAdditional volume: 1.98 crore litresExisting order value: around ₹400 croreExisting order volume: ~47.9k KLSupply deadline: அக்டோபர் 2026Additional order vs TTM revenue: ~42.4%
📅 குறுகிய காலம்Positive sentiment driver as the sizable allocation confirms OMC demand and utilization ramp-up for the distillery segment through October 2026.
📈 நீண்ட காலம்Validates the company's strategic transition toward grain-based ethanol manufacturing, establishing scale and operational track record with state-run OMCs under the national blending programme.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility (grain feedstock) impacting distillery gross margins
Customer concentration risk with government-backed OMC offtake agreements
Execution and delivery adherence risks within the October 2026 timeframe
👀 கவனிக்க வேண்டியவை
Track quarterly ethanol execution volumes and operating margins in upcoming quarterly results, alongside progress on feedstock procurement and capacity utilization through October 2026.
Modi Naturals Q1 FY27 PAT up 19% to ₹12.5 Cr; Secures ₹140 Cr Additional Ethanol Order
Modi Naturals reported a 25.6% YoY rise in consolidated EBITDA to ₹22.2 Cr and a 19.1% YoY increase in PAT to ₹12.5 Cr for Q1 FY27, despite flat revenue at ₹155.6 Cr. Profitability was driven by the Ethanol division, where EBITDA margins expanded 510 bps YoY to 22.2% even with a 20-day maintenance shutdown. The company secured an additional ₹140 Cr order from OMCs for the balance Ethanol Supply Year (ESY) through October 2026, representing ~42.4% of TTM revenue (₹330 Cr). The expanded ethanol capacity of 282 KLPD (up from 130 KLPD in FY24) is scheduled to be fully operational by the end of August 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுModi Naturals published its August 2026 investor presentation detailing Q1 FY27 results, a fresh ₹140 Cr OMC ethanol order, and the operationalization timeline for its 282 KLPD ethanol capacity expansion.
ஏன் இது முக்கியம்Higher ethanol capacity coupled with strong margins (22.2%) provides strong revenue visibility and operating leverage heading into H2 FY27.
📅 குறுகிய காலம்Successful ramp-up of the expanded ethanol unit by end of August 2026 will support higher production and revenue recognition over Q2 and Q3 FY27.
📈 நீண்ட காலம்Doubling ethanol capacity alongside FMCG brand expansion in quick commerce supports sustained top-line scaling and structural margin improvement.
⚠ அபாய எச்சரிக்கைகள்
Ethanol raw material pricing fluctuations (e.g., FCI rice) and regulatory dependency on government offtake pricing.
Thin margins in consumer edible oil bulk business amid commodity price volatility.
👀 கவனிக்க வேண்டியவை
Monitor the commercial ramp-up of the expanded 282 KLPD ethanol facility post-August 2026 and track delivery timelines of the ₹140 Cr OMC order book.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Q1 Net Profit Up 19.1% YoY to ₹12.50 Cr; Revenue Flat at ₹155.61 Cr
Modi Naturals reported a 19.1% YoY increase in consolidated Net Profit to ₹12.50 Cr for Q1 FY27 (quarter ended June 30, 2026), compared to ₹10.49 Cr in Q1 FY26. Consolidated Revenue from Operations remained virtually flat at ₹155.61 Cr versus ₹155.03 Cr in the year-ago period. Standalone edible oil business contributed ₹80.80 Cr in revenue and ₹2.88 Cr in PAT, with wholly owned subsidiary Modi Biotech Private Limited driving the remainder of consolidated performance. Diluted EPS rose to ₹9.44 from ₹7.87 in Q1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its unaudited standalone and consolidated Q1 FY27 financial results showing steady revenue and margin-driven profit expansion.
ஏன் இது முக்கியம்Demonstrates sustained operational profitability from the consolidated entity (including the ethanol division) despite flat top-line growth in core agricultural/bulk segments.
Consolidated Revenue (Q1): ₹155.61 கோடிConsolidated PAT (Q1): ₹12.50 கோடிConsolidated PBT (Q1): ₹15.95 கோடிDiluted EPS: ₹9.44Standalone Revenue (Q1): ₹80.80 கோடி
📅 குறுகிய காலம்Positive for the stock due to robust bottom-line growth YoY, though sequential revenue moderated from Q4 levels.
📈 நீண்ட காலம்Long-term trajectory depends on execution of the ethanol expansion strategy and scaling higher-margin branded consumer products.
⚠ அபாய எச்சரிக்கைகள்
Seasonal volatility in raw material supplies for the bulk oil business
Dependence on government-mandated ethanol blending policies and offtake pricing
👀 கவனிக்க வேண்டியவை
Track capacity utilization and policy developments in the ethanol subsidiary (Modi Biotech), alongside branded consumer volume growth in upcoming quarterly results.
Modi Naturals Q4 FY26 PAT Surges 141% to ₹19.7 Cr; Ethanol Capacity Doubled to 282 KLPD
Modi Naturals reported a strong Q4 FY26 with revenue growing 28% to ₹243 crore and PAT jumping 141% to ₹19.7 crore. The company successfully commissioned Phase 2 of its ethanol expansion, more than doubling capacity to 282 KLPD, which is expected to drive significant growth in FY27. Operational efficiency improved with ROCE rising to 19.9% and working capital days reducing to 62. The consumer division also hit a record quarterly revenue of ₹50.9 crore, supported by growth in the pasta and packaged foods categories.
முக்கிய அம்சங்கள்
Q4 FY26 PAT increased by 141% YoY to ₹19.7 crore, while EBITDA grew 51.8% to ₹24.5 crore.Ethanol capacity expanded from 130 KLPD to 282 KLPD, with a current order book of ₹400 crore for 47.9k KL.Full-year FY26 ROCE improved to 19.9% from 18.3%, reflecting better capital productivity and earnings quality.Consumer division achieved its highest-ever quarterly revenue of ₹50.9 crore in Q4 FY26.Cash flow from operations strengthened to ₹61.1 crore for FY26 compared to ₹48.8 crore in FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization levels of the newly expanded ethanol capacity in FY27, as this will be the primary driver for margin expansion. The company's shift toward a branded consumer portfolio and improved working capital management makes it a strong watch in the FMCG and Bio-energy space.
Modi Naturals FY26 PAT Jumps 62% to ₹50.3 Cr; Targets Up to ₹965 Cr Revenue for FY27
Modi Naturals delivered a robust FY26 performance with consolidated revenue growing 8.5% YoY to ₹719.2 crore and PAT surging 62.1% to ₹50.3 crore. The growth was primarily driven by the Ethanol division, where capacity expanded 117% over two years to 282 KLPD, and improved operational efficiencies. The company strengthened its balance sheet by reducing its Debt/Equity ratio from 1.22 to 0.94 and improving ROCE to 19.9%. Management has issued aggressive guidance for FY27, targeting revenue between ₹925-965 crore and EBITDA of ₹100-105 crore.
முக்கிய அம்சங்கள்
FY26 Revenue grew 8.5% to ₹719.2 cr, while EBITDA increased 31.2% to ₹73.5 cr with a margin of 10.2%.PAT rose 62.1% to ₹50.3 cr, which includes a ₹4.9 cr insurance claim for business interruption.Ethanol capacity reached 282 KLPD following Phase II commencement, with a ₹400 cr order book from OMCs.Net Working Capital days improved to 62 days from 66 days, and Debt/Equity reduced to 0.94.FY27 guidance projects significant growth with Revenue targets of ₹925-965 cr and PAT of ₹66-70 cr.
👀 கவனிக்க வேண்டியவை
The company is at an inflection point with its Ethanol division becoming a major growth engine alongside a steady consumer business. Investors should watch for the successful ramp-up of Phase II ethanol utilization and the achievement of the ambitious FY27 revenue guidance.
Modi Naturals Appoints B. Chhawchharia & Co as New Statutory Auditors
Modi Naturals Limited has announced the resignation of its statutory auditor, M/s Doogar & Associates, effective May 13, 2026. The Board has concurrently approved the appointment of M/s B. CHHAWCHARIA & CO. to fill the casual vacancy, subject to shareholder approval. This transition aims to align audit processes across the group, as the new firm already audits the company's material subsidiary, Modi Biotech Private Limited. The move is intended to enhance operational synergies and consistency in financial reporting.
முக்கிய அம்சங்கள்
Resignation of M/s Doogar & Associates effective May 13, 2026Appointment of M/s B. CHHAWCHARIA & CO. (FRN: 305123E) to fill the casual vacancyNew auditor already serves the material subsidiary, Modi Biotech Private LimitedStrategic move to ensure consistency in audit processes and operational synergies across the Group
👀 கவனிக்க வேண்டியவை
Investors should note the change as a routine governance update aimed at group-level efficiency; monitor the upcoming General Meeting for formal shareholder approval.
Modi Naturals FY26 Net Profit Jumps 94% to ₹60.28 Cr; Revenue Up 8.5%
Modi Naturals reported a robust performance for the financial year ended March 31, 2026, with consolidated net profit nearly doubling to ₹60.28 crore from ₹31.03 crore in the previous year. Annual revenue from operations grew by 8.5% YoY to reach ₹719.18 crore. The fourth quarter was exceptionally strong, with net profit surging 141% YoY to ₹19.67 crore. Additionally, the company announced a change in statutory auditors and the shifting of its registered office to its corporate premises.
முக்கிய அம்சங்கள்
Consolidated Net Profit for FY26 rose 94.3% YoY to ₹60.28 crore.Annual Revenue from Operations increased to ₹719.18 crore compared to ₹662.91 crore in FY25.Q4 FY26 Net Profit saw a massive jump of 141% YoY, reaching ₹19.67 crore.Basic Earnings Per Share (EPS) improved significantly to ₹38.01 from ₹23.25 in the previous year.Appointment of M/s B. CHHAWCHARIA & CO. as new Statutory Auditors following the resignation of M/s Doogar & Associates.
👀 கவனிக்க வேண்டியவை
The significant expansion in profit margins and strong Q4 performance are very positive; however, investors should monitor the auditor transition to ensure continued reporting transparency.
Modi Naturals Credit Rating Upgraded to IVR BBB/Stable for Rs 65 Crore Bank Facilities
Infomerics Valuation and Ratings has upgraded the credit ratings for Modi Naturals Limited's bank facilities totaling Rs. 65.00 crore. The long-term rating has been revised upward to IVR BBB with a Stable outlook, while the short-term rating has been upgraded to IVR A3+. This upgrade is based on the company's improved operational and financial performance during FY25 and the first nine months of FY26. The rated facilities include a Rs. 55 crore Cash Credit and a Rs. 10 crore Letter of Credit/Bank Guarantee.
முக்கிய அம்சங்கள்
Long-term rating upgraded to IVR BBB/Stable for Rs. 55.00 crore Cash Credit facilityShort-term rating upgraded to IVR A3+ for Rs. 10.00 crore non-fund based facilitiesTotal bank loan facilities reviewed and rated amount to Rs. 65.00 croreRating revision reflects positive financial performance evaluation for FY25 and 9MFY26
👀 கவனிக்க வேண்டியவை
Investors should view this credit upgrade as a positive indicator of the company's improving financial health and reduced credit risk. This could potentially lead to lower borrowing costs and better access to capital in the future.
Modi Naturals to Close Pilibhit Unit and Sell Machinery for ₹63 Lakhs
Modi Naturals Limited has announced the closure of its manufacturing unit in Pilibhit, Uttar Pradesh, citing operational non-viability. The unit contributed approximately ₹16 crores (4%) to the company's standalone turnover and ₹90 lakhs (0.81%) to its net worth in the last financial year. The company is selling the plant and machinery for ₹63 lakhs while retaining the land and building assets. Management expects no material adverse impact as production will be absorbed by another nearby facility with spare capacity.
முக்கிய அம்சங்கள்
Closure of Pilibhit manufacturing unit due to non-viability of operationsUnit contributed ₹16 crores (4% of standalone turnover) and ₹90 lakhs (0.81% of net worth)Plant and machinery sold for ₹63 lakhs to a non-promoter buyer; land and building retainedProduction volumes to be absorbed by a nearby solvent extraction plant with adequate spare capacityTransaction expected to be completed by April 23, 2026
👀 கவனிக்க வேண்டியவை
This is a strategic consolidation move to eliminate a non-viable unit with minimal impact on overall revenue. Investors should monitor if the consolidation leads to improved margins in the bulk oil segment.
Modi Naturals Doubles Ethanol Capacity to 282 KLPD at Chhattisgarh Plant
Modi Naturals' wholly-owned subsidiary, Modi Biotech Private Limited, has commenced commercial operations at its expanded grain-based ethanol plant in Chhattisgarh. The facility's capacity has been significantly increased from 130 KLPD to 282 KLPD, representing a 117% expansion in production capability. This strategic move aligns with the Government of India's Ethanol Blended Petrol (EBP) Programme, positioning the company to benefit from rising biofuel demand. The expansion is expected to enhance operational efficiencies and contribute meaningfully to the company's revenue growth in the coming quarters.
முக்கிய அம்சங்கள்
Ethanol production capacity enhanced from 130 KLPD to 282 KLPDCommencement of commercial operations at the expanded facility of subsidiary Modi Biotech Private LimitedStrategic alignment with the Government of India's Ethanol Blended Petrol (EBP) ProgrammeExpected to drive higher production volumes and improve overall operational efficiencies
👀 கவனிக்க வேண்டியவை
Investors should view this as a major growth milestone that significantly scales the company's high-margin ethanol business. Monitor the upcoming quarterly results for the impact of this capacity ramp-up on the company's profitability and revenue mix.
Modi Naturals reported a strong 28.5% YoY growth in Q3FY26 PAT to ₹10.0 crore, despite a 2.8% dip in consolidated revenue to ₹174.1 crore. For the 9MFY26 period, PAT rose 33.9% to ₹30.6 crore, driven by improved operating leverage and lower finance costs from debt repayment. However, the company has lowered its FY26 revenue guidance to ₹720-730 crore from ₹850-880 crore due to delays in commissioning its 180 KLPD ethanol expansion. The ethanol division remains the primary growth catalyst, with total capacity set to reach 310 KLPD by the end of February 2026.
முக்கிய அம்சங்கள்
Q3FY26 PAT increased by 28.5% YoY to ₹10.0 crore, while EBITDA grew 20.7% to ₹16.0 crore.9MFY26 EBITDA margins expanded to 10.3% from 8.4% YoY, aided by softer raw material costs and lower finance charges.Ethanol capacity expansion of 180 KLPD is scheduled for commissioning by late February 2026, taking total capacity to 310 KLPD.FY26 revenue guidance slashed to ₹720-730 crore (previously ₹850-880 crore) due to ethanol project delays.Consumer division revenue stood at ₹46.3 crore in Q3, showing resilience despite GST-related billing disruptions in October 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful commissioning and ramp-up of the 180 KLPD ethanol facility in Q4, as this is critical for meeting revised targets. While the guidance cut is a short-term negative, the improving margin profile and debt reduction are positive indicators for long-term stability.
Modi Naturals Q3 Net Profit Rises 28% YoY to ₹10.04 Cr Despite Marginal Revenue Dip
Modi Naturals reported a consolidated net profit of ₹10.04 crore for the quarter ended December 31, 2025, representing a 28.5% growth compared to ₹7.82 crore in the previous year. While revenue from operations saw a slight decline of 2.7% YoY to ₹174.09 crore, the company significantly improved its bottom line through reduced finance costs and strong subsidiary performance. For the nine-month period, PAT surged by 33.9% to ₹30.61 crore. The subsidiary, Modi Biotech Private Limited, played a crucial role, contributing ₹81.19 crore to the quarterly revenue and ₹8.92 crore to the profit.
முக்கிய அம்சங்கள்
Consolidated Net Profit increased to ₹10.04 crore in Q3 FY26 from ₹7.82 crore in Q3 FY25.Revenue from operations stood at ₹174.09 crore, down slightly from ₹179.02 crore YoY.Finance costs decreased significantly to ₹1.82 crore from ₹3.14 crore in the year-ago quarter.Subsidiary Modi Biotech Private Limited contributed ₹81.19 crore in revenue and ₹8.92 crore in PAT for the quarter.Nine-month PAT grew to ₹30.61 crore compared to ₹22.86 crore in the corresponding period last year.
👀 கவனிக்க வேண்டியவை
Investors should note the strong profitability growth driven by the biotech subsidiary and efficient cost management. The reduction in finance costs suggests improving financial health, making it a stock to watch for further margin expansion.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
